Why Apogee Therapeutics, Inc. (APGE) stock moved
Apogee Therapeutics, Inc. (APGE) shares rose 0.0% to $134.97 as of August 30, 2026, a slight gain from the prior close of $134.96. BestStocks flagged the session as a major change for APGE. Below, we break down what changed for APGE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
APGE climbed 0.0% to $134.97
Apogee Therapeutics, Inc. (APGE) filed an 8-K on August 11, 2026. The filing content was not disclosed in available sources. APGE earnings scheduled for November 9, 2026 (consensus EPS estimate: −$1.14).
What it means for Apogee Therapeutics, Inc. investors
For Apogee Therapeutics, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.0% session move; Apogee Therapeutics, Inc. (APGE) moved +0.25% from $133.96 to $134.29 on 2026-07-15, reaching a new 30-day high. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $130.92, implying -3.0% downside from $134.97. Over the past 90 days analysts logged 0 upgrades and 10 downgrades. BestStocks rates the overall signal quality weak (17/100). With earnings roughly 71 days out, the next report is the most likely near-term test of the move.
APGE price reaction
APGE last traded at $134.97, up $0.01 (+0.01%) from the previous close of $134.96. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $134.09 and $134.97, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Apogee Therapeutics, Inc. (APGE)
The consensus analyst price target on Apogee Therapeutics, Inc. (APGE) is $130.92, 3.0% below the recent $134.97. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 10 downgrades. Here is how the bullish and bearish cases on APGE line up.
The bullish case
- The Street's most bullish target is $140.00 (+3.7%).
- Positive 0.0% session move.
- Apogee Therapeutics, Inc. (APGE) moved +0.25% from $133.96 to $134.29 on 2026-07-15, reaching a new 30-day high.
The bearish case
- The consensus analyst price target of $130.92 sits 3.0% below the recent $134.97, so the average target sees limited room to run.
- The most bearish analyst target is $89.00 (-34.1%).
- 10 analyst downgrades in the past 90 days, most recently BTIG to Neutral (2026-08-12).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for APGE
Frequently asked questions about APGE
Why did Apogee Therapeutics, Inc. (APGE) stock move?
APGE rose 0.0% to $134.97. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did APGE stock rise?
APGE gained 0.01% ($0.01) versus the prior close of $134.96, last trading at $134.97 on 0.2× average volume.
When is Apogee Therapeutics, Inc.'s next earnings date?
APGE's next earnings report is estimated for 2026-11-09 — about 71 days away.
What is the analyst price target for APGE?
The consensus analyst price target for APGE is $130.92, about 3.0% below the current $134.97. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 10 downgrades.
How BestStocks tracks APGE
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared APGE-specific materiality thresholds, triggering an evidence check. It draws on 14 tracked change events for APGE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.